Across TCGA pan-cancer cohorts, FSIP2 mass-spec protein differs between tumor and matched normal tissue in 1 of 18 cancer types tested, making tumor–normal expression one of FSIP2’s most consistent transcriptional readouts.
The strongest signal is observed in lung adenocarcinoma (LUAD), where FSIP2 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types FSIP2 is over-expressed in tumor, although a few such as LUAD show the opposite, repressed pattern.
LUAD are the cancer types where FSIP2 tumor–normal differential expression is most reproducible.